[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oxaliplatin-induced-peripheral-neuropathy-in-cancer-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oxaliplatin-induced-peripheral-neuropathy-in-cancer-patients":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100632275","prospective-exploratory-study-of-a-multiomic-blood-biomarker-panel-to-predict-chemotherapy-induced-peripheral-neuropathy-cipn-100632275",false,"NCT07511569","Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)","PRECISE1","Inclusion Criteria:\n\n* Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study\n* Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more\n* Age \\> 18 years\n* Life expectancy \\> 3 months\n* Patient affiliated with or entitled to social security\n\nExclusion Criteria:\n\n* Patients already suffering from neuropathy or chronic neurogenic pain\n* Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)\n* Patients who have already received neurotoxic cancer treatment including those in clinical trials\n* Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)\n* Patients receiving immunotherapy","ALL",{"count":18,"type":19},192,"ESTIMATED","OBSERVATIONAL","The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.",[23,24,25,26],"Chemotherapy Induced Neuropathic Pain","Neuropathy Toxic","Taxane-induced Peripheral Neuropathy","Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","NOT_YET_RECRUITING","2026-04-07",{"date":30,"type":31},"2026-04-13","ACTUAL",{"date":33,"type":19},"2027-01-04",{"date":35,"type":19},"2029-06-04",{"name":37,"class":38},"Centre Hospitalier de Bligny","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100623663","effect-of-exercise-on-chemotherapy-induced-peripheral-neuropathy-100623663","NCT07399561","Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy","A Randomized Controlled Trial Evaluating the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy in Patients Treated With Oxaliplatin or Paclitaxel","EX-CIPN","Inclusion Criteria:\n\n* Diagnosis of colorectal cancer (oxaliplatin cohort) or gynecologic cancer (paclitaxel cohort)\n* Planned initiation of oxaliplatin- or paclitaxel-based chemotherapy\n* Karnofsky Performance Status ≥70\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Pre-existing peripheral neuropathy from other causes\n* Severe comorbidities limiting safe participation in exercise\n* Regular participation in a structured moderate- to high-intensity exercise program comparable to the study intervention prior to enrollment.\n* Cognitive impairment interfering with study participation","19 Years","75 Years",{"count":50,"type":19},140,"INTERVENTIONAL",[53],"NA","Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of oxaliplatin- and paclitaxel-based chemotherapy. While exercise is frequently recommended for patients with CIPN, it remains unclear whether exercise mitigates neuropathic injury itself or primarily improves physical function and quality of life.\n\nThis randomized controlled trial evaluates the effects of exercise on CIPN during and after chemotherapy. Patients receiving oxaliplatin for colorectal cancer or paclitaxel for gynecologic cancer are randomized to an exercise intervention or usual-care control. Neuropathy severity is assessed using objective neurophysiological measures, blood biomarkers, and validated clinical and patient-reported outcomes.",[56,26,57],"Peripheral Neuropathy, Secondary to Drugs or Chemicals","Paclitaxel Induced Neuropathy",[59,60,61],"chemotherapy induced peripheral neuropathy","CIPN","Exercise","2026-02-02",{"date":64,"type":31},"2026-02-10",{"date":66,"type":19},"2026-02-03",{"date":68,"type":19},"2027-12-31",{"name":70,"class":71},"National Cancer Center, Korea","OTHER_GOV",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":51,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":72},"100605817","early-phase-1-neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy-100605817","NCT07167446","Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy","Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study","Inclusion Criteria:\n\n1. Patients with metastatic, locally advanced unresectable colorectal cancer patients planned to receive Ox based chemotherapy in metastatic setting (at least 3 months planned).\n2. Subjects are allowed to have one cycle of Ox based chemotherapy before enrollment.\n3. ECOG PS 0-2\n4. No prior platinum exposure\n5. No evidence of ongoing neuropathy of any grade at the time of enrollment\n6. Patients must have marrow and organ function appropriate for systemic therapy, as per physician's discretion, but liver function should meet criteria below:\n\n   1. Total Bilirubin: less than and\u002For equal to 1.5 X ULN\n   2. AST(SGOT)\u002FALT(SGPT): less than and\u002For equal to 3 X ULN (5 X ULN in patients with liver metastases\n7. Ability to understand and willingness to sign a written informed consent and HIPAA consent document.\n\n   Exclusion Criteria:\n8. Family history of genetic\u002Ffamilial neuropathy and personal history of ongoing neuropathy (any grade) or nervous system disease with the potential to affect cognition, Parkinson's disease, or multiple sclerosis.\n9. Routine use of recreational marijuana products (defined as \\> 4 times per month) or illicit drug use per self-reported history within the last 90 days. If using medical cannabis products, it should be stopped at least 1 week prior to inclusion.\n10. Known underlying liver disease (Child-Pugh B or C) or baseline elevation of total bilirubin greater than and\u002For equal to 1.5 x upper limit of normal based on screening laboratory values.\n11. 1Untreated brain metastases (can increase seizure risk), or treated brain metastases on anti-seizure medications.\n12. Patients being treated with anti-seizure or anti-psychotic medications. Patients with a prior history of anti-seizure medication use, who have been off treatment for more than 3 months, are eligible. Use of Selective Serotonin Reuptake Inhibitors (SSRIs) is permitted.\n13. Concomitant treatment with strong inducers of CYP3A4 and\u002For strong inducers of CYP2C19.\n14. Underlying history of epilepsy\u002Frecurrent seizure disorder or unexplained seizure within past 6 months.\n15. Patients with current or lifetime diagnosis of schizophrenia spectrum disorder, psychotic disorder, bipolar disorder type I \\& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic), eating disorders, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revised (DSM-5-TR, APA 2022)\n16. Recent history or clinical concern for major depression with suicidal ideation as determined by investigator assessment at baseline\n17. Currently taking medications known to be contraindicated with Epidiolex -FDA-approved CBD (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine, valproate).\n18. Women who are pregnant or breastfeeding, and individuals of any sex who are capable of reproduction and unwilling to use an effective form of birth control (e.g., condoms, diaphragm, birth control pills, or IUD).\n19. Patients may not be receiving any other investigational agents.","18 Years",{"count":82,"type":19},30,[84],"EARLY_PHASE1","This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.",[26,87,88],"Metastatic Colorectal Cancer (CRC)","Peripheral Neuropathy Due to Chemotherapy",[90,91,92,93],"Oxaliplatin-Induced Peripheral Neuropathy (OIPN)","Cannabidiol (CBD)","Colorectal Cancer (CRC)","Neuroprotection","RECRUITING","2025-10-20",{"date":97,"type":31},"2025-10-22",{"date":99,"type":31},"2025-10-14",{"date":101,"type":19},"2028-09-07",{"name":103,"class":38},"Fox Chase Cancer Center"]